...Medicines Co. gained MDCO-2010 through its 2008 acquisition of Curacyte Discovery GmbH, a subsidiary of Curacyte AG...

...deal facilitated by dievini Hopp (see BioCentury, March 2, 2009) . Among other recent setbacks, Curacyte AG...
...that acts as a nitric oxide scavenger. AX200 is a recombinant granulocyte-colony stimulating factor (G-CSF). Curacyte...
...update on its plans. dievini Hopp initially invested €12 million ($15.7 million) as part of Curacyte's...

...Medicines Co. gained MDCO-2010 through its 2008 acquisition of Curacyte Discovery GmbH, a subsidiary of Curacyte AG...

...planned 454 patients, will not meet the primary endpoint of all-cause mortality at 28 days. Curacyte...
...plus vasopressor therapy in patients with catecholamine-resistant distributive shock for a maximum of 150 hours. Curacyte...
...said hemoximer is the company's only asset. The company would not comment on next steps. Curacyte AG...

...distributive shock for a maximum of 150 hours. Hemoximer is a nitric oxide (NO) scavenger. Curacyte...

...plus vasopressor therapy in patients with catecholamine-resistant distributive shock for a maximum of 150 hours. Curacyte AG...

...its recent deal for ApoA-I Milano from Pfizer Inc. (NYSE:PFE) as well as acquisitions of Curacyte...
...not feasible or desirableC. 8/5/08 - Acquires Curacyte Discovery GmbH for €14.5M ($22.6M), thus obtaining Curacyte's...

...the $42 million paid upfront. In an earlier pipeline filling, Medicines Co. acquired Curacyte AG 's Curacyte...
...small molecule serine protease inhibitor that was in preclinical testing to prevent surgical blood loss. Curacyte...
...Germany Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Lexington, Mass. Curacyte AG...

...a continuous IV infusion in more than 450 patients unresponsive to standard therapy with catecholamines. Curacyte AG...

...inhibitors and evaluating the candidates in preclinical CLL models. CD 160130, a PDE4 inhibitor from Curacyte AG...